Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05386043 · ClinicalTrials.gov registry record
Registering Genomics and Imaging of Tumors (ReGIT)
A clinical trial of Glioma, sponsored by Indiana University.
- Recruiting
- Registry status
- 20
- Enrollment target
- 1
- Study location
NCT05386043: Recruiting study of Glioma, sponsored by Indiana University.
NCT05386043 is a study of Glioma that is actively recruiting participants, run by Indiana University. The registered enrollment target is 20 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05386043, a study of Glioma, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is investigating how brain tumors might mutate over time, and whether new brain imaging tools like MRI and PET can predict these mutations.
Primary Outcome
Statistical evaluation of the area under the ROC curve. 3.1.1 SMM classification sensitivity to \>80% 3.1.2 Reduce computation time by a factor of 10, and maintain accuracy (\>.95)
Conditions Studied
Interventions
- DRUG FET F-18
- DRUG O-15 Radioisotope
- PROCEDURE CT scan
- PROCEDURE MRI with gadolinium-based contrast
- PROCEDURE Biopsy Collection
Study Locations (1)
Indiana
- Indiana University School of Medicine - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-07-18 |
| Est. Completion | 2032-07-17 |
What NCT05386043 shows while recruiting
NCT05386043 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Glioma appearing as the primary indexed condition, and to 5 interventions - of which FET F-18 is the first listed.
NCT05386043 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT05386043 about?
NCT05386043 is a clinical study titled "Registering Genomics and Imaging of Tumors (ReGIT)". This study is investigating how brain tumors might mutate over time, and whether new brain imaging tools like MRI and PET can predict these mutations.
What is the current status of trial NCT05386043?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2023-07-18. Estimated completion is 2032-07-17.
What conditions does trial NCT05386043 study?
This clinical trial studies the following conditions: Glioma.
What interventions are being tested in trial NCT05386043?
The interventions under investigation include: FET F-18 (DRUG), O-15 Radioisotope (DRUG), CT scan (PROCEDURE), MRI with gadolinium-based contrast (PROCEDURE), Biopsy Collection (PROCEDURE).
Who is sponsoring clinical trial NCT05386043?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05386043 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05386043's enrollment target sits among peer trials
20 65th of 87 higher than 18 of 87 other Glioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
RECRUITING · Phase 2
-
Tumor Treating Fields for the Treatment of Brainstem Gliomas
RECRUITING · NA
-
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
RECRUITING · Phase 4
-
Cognitive Changes of IDH-mutant and IDH-wildtype Glioma Patients After Chemoradiotherapy With Radiation Dose to the Resting State Networks
RECRUITING
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI